Investcorp has announced that Lu Daopei Medical (LDP) has partnered with Florence Nightingale Hospital Group in Turkey to establish the MENA region’s first dedicated CAR-T stem cell therapy center focused on the treatment of severe leukemia, including pediatric cases.
Lu Daopei Medical (LDP) is a portfolio company of the Investcorp China Pre-IPO Healthcare Fund.
The partnership brings world-class CAR-T (Chimeric Antigen Receptor T-cell) therapy, developed and refined in China, to the Middle East for the first time.
CAR-T therapy is an advanced form of immunotherapy that modifies a patient’s own immune cells to recognize and eliminate cancer cells more effectively. Through the partnership, LDP aims to create capacity for up to 200 CAR-T treatments annually, with plans to expand into broader oncology applications over time.
Mohammed Alardhi Executive Chairman Investcorp
“We are proud to support Lu Daopei Medical’s partnership with Florence Nightingale Hospital Group to bring advanced CAR-T cell therapy to the region. This initiative reflects our commitment to backing innovative healthcare companies that deliver meaningful impact by expanding access to cutting-edge treatment options for patients who need them most.”
Duncan Zheng, Head of Investcorp China and Deputy Head of Emerging Markets Private Equity, said that, “The launch of the center demonstrates the strength of cross-border collaboration and our ability to support portfolio companies in transferring proven clinical innovation into new markets. We see significant potential to further expand access to these therapies across the region as demand for specialized oncology care continues to grow.”
The establishment of the CAR-T center strengthens regional healthcare infrastructure, reduces the need for patients to travel abroad for treatment, and positions the Middle East as an emerging hub for next-generation cell therapy and oncology care.
